ArticleFrontiers in medicine2021
Palindromic Rheumatism: Just a Pre-rheumatoid Stage or Something Else?
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.Nature medicine · 2026Trial
- Palindromic Rheumatism: Revisiting the Approach to an Enigmatic Condition.International journal of rheumatic diseases · 2026Article
- Association between body mass index and palindromic rheumatism risk and outcomes: a case-control study.Clinical rheumatology · 2026Article
- Comparing clinical outcomes of rheumatoid arthritis by onset type: palindromic rheumatism, undifferentiated arthritis, and typical rheumatoid arthritis.Clinical rheumatology · 2026Article
- Molecular analysis of TNFAIP3, PTPN22, IRF5, and IL-10 gene polymorphisms in palindromic rheumatism.Clinical rheumatology · 2025Article
- Efficacy of iguratimod in the treatment of patients with palindromic rheumatism ineffective to methotrexate or hydroxychloroquine.Frontiers in immunology · 2025Article
- The So-Called Pre-Clinical Rheumatoid Arthritis: Doubts, Challenges, and Opportunities.Journal of clinical medicine · 2024Article
- Performance of existing diagnostic criteria for palindromic rheumatism.Clinical rheumatology · 2024Article
- A 40-Year-Old Man with a 7-Year History of Polyarthritis and a Late Diagnosis of Whipple Disease: A Journey to Resolve the Mystery.The American journal of case reports · 2024Article
- Article
- Implications of Post-Translational Modifications in Autoimmunity with Emphasis on Citrullination, Homocitrullination and Acetylation for the Pathogenesis, Diagnosis and Prognosis of Rheumatoid Arthritis.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palindromic rheumatism (PR), a unique clinical entity, has a characteristic clinical presentation with a relapsing/remitting course. It is established that most patients with PR evolve to chronic disease, of which rheumatoid arthritis (RA) is by far the most common. The relationship between PR and RA is unclear, with similarities and differences between the two, and not all patients evolve to RA in the long-term. Therefore, PR is clearly a pre-RA stage for most, but not all, patients. Autoimmunity plays a substantial role in PR, with the same characteristic autoantibody profile observed in RA, although with some differences in the immune response repertoire. Autoinflammation may also be relevant in some cases of PR. Prognostic factors for RA progression are identified but their exact predictive value is not clear. There are several unmet needs in PR, such as the diagnostic criteria and clinical case definition, the pathogenic mechanisms involved in the unusual clinical course, and the evolution to RA, and our understanding of the therapeutic strategy that could best avoid progression to persistent and potentially destructive arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.